{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:55:34Z","timestamp":1761173734026,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"am","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.purol.2021.09.010","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T19:26:46Z","timestamp":1635449206000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of carcinoma in situ on survival of patients treated by adjuvant chemotherapy after cystectomy"],"prefix":"10.1016","volume":"32","author":[{"given":"Y.","family":"Soorojebally","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-9684","authenticated-orcid":false,"given":"L.","family":"Surlemont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4345-3598","authenticated-orcid":false,"given":"Y.","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lebret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2021.09.010_bib0110","unstructured":"Cancer today 2020 [Internet]; Available from: http:\/\/gco.iarc.fr\/today\/home [cited 2021 Jun 29]."},{"key":"10.1016\/j.purol.2021.09.010_bib0115","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1166-7087(20)30751-X","article-title":"[French ccAFU guidelines \u2013 update 2020\u20132022: bladder cancer]","volume":"30","author":"Roupr\u00eat","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0120","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0125","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.urolonc.2019.04.006","article-title":"Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer","volume":"37","author":"Macleod","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.purol.2021.09.010_bib0130","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.eururo.2012.01.039","article-title":"Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire","volume":"61","author":"Burger","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0140","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.purol.2021.09.010_bib0145","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","article-title":"Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review","volume":"67","author":"Casey","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0150","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.euf.2019.03.012","article-title":"Carcinoma in situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes","volume":"6","author":"Subiela","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.purol.2021.09.010_bib0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer","volume":"163","author":"Mill\u00e1n-Rodr\u00edguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0160","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.juro.2018.05.162","article-title":"Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: a systematic review and meta-analysis","volume":"201","author":"Kimura","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0165","doi-asserted-by":"crossref","first-page":"850.e1","DOI":"10.1016\/j.urolonc.2020.06.014","article-title":"Urothelial carcinoma in situ response to cisplatin-based neoadjuvant chemotherapy, or lack thereof: Impact on patient selection for organ preservation in muscle-invasive disease?","volume":"38","author":"Tachibana","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.purol.2021.09.010_bib0170","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.juro.2014.11.003","article-title":"The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival","volume":"193","author":"Parker","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0175","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.clgc.2016.11.009","article-title":"Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy","volume":"15","author":"Thomas","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.purol.2021.09.010_bib0180","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1442-2042.2008.02000.x","article-title":"Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer","volume":"15","author":"Muramaki","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0185","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.juro.2012.08.017","article-title":"Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients","volume":"188","author":"Picozzi","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2021.09.010_bib0190","doi-asserted-by":"crossref","first-page":"E217","DOI":"10.5489\/cuaj.119","article-title":"Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort","volume":"6","author":"Power","year":"2012","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.purol.2021.09.010_bib0195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","article-title":"Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer","volume":"34","author":"Galsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2021.09.010_bib0200","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.purol.2021.09.010_bib0205","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.purol.2021.09.010_bib0210","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708721004747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708721004747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:35:00Z","timestamp":1761114900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708721004747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1166708721004747"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2021.09.010","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of carcinoma in situ on survival of patients treated by adjuvant chemotherapy after cystectomy","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2021.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}